Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10 of patients with cutaneous psoriasis. Bristol-Myers Squibb, Orencia (Abatacept) Product Monograph, Bristol-Myers Squibb. The PAUSE study is testing the combination of two biologics, ustekinumab (Janssen Biotech, Inc.) and abatacept (Bristol-Myers Squibb), in psoriasis patients. Activated T-cells are present in inflamed joints of patients with psoriasis. Abatacept (Orencia, Bristol-Myers Squibb), a new biologic agent indicated for use as a first-line treatment for rheumatoid arthritis, effectively inhibits T-cell co-stimulation by blocking the interaction of lymphocyte function-associated antigen 3 (LFA-3) with CD2.
Biologic. Immunoscience. Belatacept. NULOJIX. M. Biologic. Immunoscience. Anti-CD40. 1. Biologic. Immunoscience. Abatacept. ORENCIA. Subjects in BMS study number IM101075 received either abatacept or placebo on a background of mycophenolate mofetil and corticosteroids. Technology evaluation: Abatacept, Bristol-Myers Squibb. Grant/Research/Clinical Trial Support: Amgen Psoriasis (Etanercept, brodalumab); Pfizer Psoriasis (tofacitinib); Bristol-Myers Squibb Psoriasis (abatacept);
Abatacept (Orencia, Bristol-Myers Squibb Company, Princeton, NJ) is a selective costimulation modulator which inhibits T cell (T lymphocyte) activation. Abatacept is considered investigational and not medically necessary for all other indications, including, but not limited to the treatment of: ankylosing spondylitis, Crohn’s disease, giant cell arteritis and Takayasu’s arteritis, graft versus host disease (GVHD), lupus nephritis, multiple sclerosis, psoriatic arthritis, psoriasis vulgaris, scleroderma, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, and uveitis. Arthritis Int Med Assoc LLC, Trumbull, CT Bristol-Myers Squibb, Princeton, NJ Bristol-Myers Squibb, Pennington, NJ Bristol-Myers Squibb, Doylestown, PA Schoen Klinik, Hamburg, Germany Seattle Rheumatology Associate, Seattle, WA Stanford University, Sunnyvale, CA. It is unclear whether the sponsor, Bristol-Myers Squibb, will seek approval to market abatacept specifically for psoriatic arthritis. Five of the 13 authors listed Bristol-Myers Squibb as their affiliation, but otherwise there was no disclosure statement for this online report.
Abatacept (Orencia, Bristol Myers Squibb) has been on the market for rheumatology as Orencia for a number of years and is moving into the psoriasis disease space. Oaks Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFa therapy. (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis. Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting23-03-2015. Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study12-06-2013. Otezla (apremilast); Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014. Orencia (abatacept); Bristol-Myers Squibb; For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008. Bristol-Myers Squibb Psoriatic arthritis Molecule CTLA-4Ig CTLA-4Ig.
Abatacept (marketed as Orencia) is drug used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. Abatacept was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNF therapy.